Infection with influenza viruses, with or without secondary bacterial pneumonia, can cause fatal lower respiratory tract infection. Children are particularly prone to influenza-induced complications such as sepsis and multiple-organ dysfunction syndrome. Before hospitalization, approximately half of all children with influenza do not have risk factors for such severe progression. 1 Variability in the host response to influenza infection may, in part, explain the variability in clinical outcomes in this population. 2 The host immune response can be impaired in children with influenza, but optimal readouts to assess immune function in these patients are not known. Understanding how the immune system is suppressed in children who develop severe influenza with lower respiratory tract infection will inform the Members of the type I IFN cytokine family, IFN-a and IFN-b, are essential for host defense against viral infection. Upon influenza infection, IFNs are secreted by innate and adaptive immune cells including macrophages, lymphocytes, and dendritic cells. 3, 4 Although type I IFN is protective and essential, it can also drive pathogenic inflammation, 5 facilitate TNF-induced shock, 6 and decrease the ability of the host immune system to cope with bacterial pathogens. 7, 8 Polyinosinic-polycytidylic acid (poly(I:C)), a synthetic oligoribonucleotide that mimics replicating double-stranded viral RNA, has been used to evaluate immune responsiveness to viral infections. [9] [10] [11] Ex vivo exposure of whole blood from children to low-molecular-weight (LMW) poly(I:C) complexed to the transfection reagent LyoVec preferentially signals via the cytoplasmic retinoic acidinducible gene-I (RIG-I) receptor, inducing production of IFN-a subtypes. 12, 13 Thus, reduced IFN-a production would be consistent with an impaired type I IFN response.
We have previously shown that reduced innate immune function is common in critically ill children with influenza infection and is associated with secondary Staphylococcus aureus infections and increased risk of mortality. 14 Innate immune function can be tested through ex vivo stimulation of whole blood samples with LPS, which activates the Toll-like receptor (TLR)4 pathway and results in the production of inflammatory cytokines including TNF-a.
It is unclear whether the type I IFN response pathway is altered in critically ill children with influenza. Furthermore, it is unknown whether the assessment of the poly(I:C)-LMW/ LyoVec-induced IFN-a response has additional predictive value beyond the LPS-induced TNF-a response in this setting. We therefore designed a multicenter, prospective, longitudinal, observational study to test the hypothesis that a combined approach to immune function monitoring via both the poly(I:C)-induced IFN-a response and the LPS-induced TNF-a response will identify children at the highest risk for adverse outcomes during critical influenza infection.
METHODS

Patient enrollment
This study was performed by the Pediatric Intensive Care Influenza investigators within the Pediatric Acute Lung Injury and Sepsis Investigators research network and approved by sites' institutional review boards. Informed consent was obtained before study participation. Children (<18 years) with confirmed influenza infection admitted to the pediatric intensive care units (PICUs) at 24 sites were eligible. Influenza was confirmed as previously described 15 or by multiplex PCR-based BioFire FilmArray (Salt Lake City, Utah). Inclusion criteria included evidence of acute pulmonary infection and requirement for invasive or noninvasive mechanical ventilation or vasoactive support. 14 In addition, to minimize the confounding effects of comorbidities on influenza outcomes, we excluded patients with chronic lung disease, symptomatic cardiac disease, neuromuscular disease, malignancy, metabolic or mitochondrial disease, known immunodeficiency, or patients who received systemic immunosuppressive medications within the previous 6 weeks.
Poly (I:C) and LPS stimulation studies
Blood was collected within the first 72 hours after PICU admission, with a second collection approximately 72 hours later, when possible. Stimulation experiments were started within an hour of blood collection. For poly(I:C) stimulation, 150 mL of heparinized whole blood was added to tubes containing 150 mL of media and stimulated with poly(I:C)-LMW/LyoVec (InvivoGen, San Diego, Calif) at a final concentration of 0.74 mg/mL 13 (for assay development details, see Table E1 in this article's Online Repository at www.jacionline.org). For purposes of brevity, this stimulant is referred to as poly(I:C) for the remainder of the article. Media-only, unstimulated blood samples served as negative controls. Samples were incubated at 378C for 24 hours. After centrifugation, supernatants were collected and frozen at 2808C for batch analysis of IFN-a2.
LPS-induced TNF-a production capacity was measured as previously described. 14 Briefly, 50 mL of heparinized blood was added to 500 mL of stimulation solution containing 500 pg/mL of LPS (highly purified via phenol extraction from Salmonella abortus equi [Enzo Life Sciences, Farmindale, NY]). Media-only, unstimulated blood samples served as negative controls. LPS-stimulated and control samples were incubated for 4 hours at 378C. After centrifugation, the supernatants were collected and frozen at 2808C for batch analysis of TNF-a.
All assays were performed in duplicate with average values reported.
Cytokine analysis
Levels of the proinflammatory mediators IFN-a2, IFN-b, TNF-a, IL-8, and IL-6 as well as the anti-inflammatory cytokine IL-10 were measured in serum, and levels of IFN-a2, IFN-b, and TNF-a generated from poly(I:C)-stimulated and control samples were measured using a multiplex array as previously described. 16 For each sample, the difference, or ''delta,'' between the average IFN-a concentration in the poly(I:C)-stimulated and unstimulated (control) tubes was calculated. A post hoc threshold of greater than or equal to 19.95 pg/mL was determined to represent high IFN-a production in the media-only control tubes based on in-house optimization assays with healthy controls as well as previous studies measuring healthy adult and pediatric IFN-a blood levels. [17] [18] [19] [20] After the poly(I:C) stimulation, subjects were classified by their response as follows: ''Suppressed'' subjects had low IFN-a levels (<19.95 pg/mL) in their control samples and were unresponsive to poly(I:C) stimulation; ''Peaked'' subjects had high levels of IFN-a (> _19.95 pg/mL) in their control samples, but were unable to mount an additional response to the poly(I:C); and those who ''Responded'' generated an absolute IFN-a increase of at least 11 pg/mL after poly(I:C) stimulation.
TNF-a levels in LPS-stimulated supernatants were measured using the Immulite 1000 automated chemiluminometer (Siemens Healthcare Diagnostics, Deerfield, Ill) as performed previously. 14 Severe suppression was characterized a priori as a TNF-a response (the TNF-a level in LPS-stimulated tube minus the TNF-a level in unstimulated control tube) of less than 200 pg/mL. 14 This predefined threshold was chosen on the basis of strong associations between a TNF-a response less than 200 pg/mL (after 4-hour incubation) and increased risks for adverse outcomes including nosocomial infection, prolonged organ dysfunction, and death in our previous work. 14, [21] [22] [23] Accordingly, a ''Suppressed'' TNF-a response was defined as less than 200 pg/mL in these analyses, with higher values defining TNF-a ''Responders.''
Clinical outcomes
Primary severity outcomes for this study were prolonged organ dysfunction (> _7 days) and mortality. Severity of illness at PICU admission was measured using the Pediatric Risk of Mortality III score. 24 The presence of acute respiratory distress syndrome, vasopressor-dependent shock, ventilator-free days, the presence of bacterial coinfections, any organ dysfunction, and prolonged acute hypoxemic respiratory failure (AHRF) were also assessed (for clinical definitions, see this article's Online Repository at www.jacionline.org).
Statistical analyses
Data were analyzed with IBM SPSS Statistics 24 (IBM Corp, Armonk, NY) using Pearson x 2 test, Kruskall-Wallis test, Wilcoxon matched-pairs signed rank test, Mann-Whitney U test, or multivariable logistic regression as appropriate. A 2-tailed P value of less than .05 was considered significant (see this article's Online Repository at www.jacionline.org).
RESULTS
Suppression of the RIG-I pathway is associated with increased risk of clinical complications
One hundred five children were enrolled from November 2012 to May 2015. Blood samples were collected within a median of 26 hours of PICU admission (interquartile range, . Ex vivo incubations were prepared within an average of 38 minutes from the time of collection. As shown in Fig 1, A, 53% of the subjects were Suppressed, failing to produce IFN-a in response to poly(I:C) stimulation. Of the remaining subjects, 36% Responded (P < .0001) and 11% Peaked. Table I presents the demographic characteristics and clinical outcomes of these 3 groups. The IFN-a Suppressed group also had low production of IL-6 and TNF-a (see Fig E1 in this article's Online Repository at www.jacionline.org). Suppressed subjects were more severely ill with acute lung injury/acute respiratory distress syndrome or shock. They also had significantly fewer ventilator-free days and longer hospital stays when compared with the other 2 patient groups. PICU length of stay among survivors was longest in the Suppressed group. The 4 fatalities, all of whom were coinfected with methicillin-resistant S aureus occurred in this group, and 3 of the 4 patients who died were infected with influenza B. There were strong trends toward fewer bacterial coinfections in the Responded group and more S aureus coinfection in the Suppressed group (both P 5 .05). Rates of corticosteroid and antiviral use were similar between groups, as were peripheral white blood cell (WBC) counts, though WBC trended lower in the Suppressed group (P 5 .07).
Suppression of both RIG-I and TLR4 pathways
For 103 of the same subjects, LPS-induced TNF-a response data were available within 72 hours of PICU admission. Baseline TNF-a levels were similar in control samples (P 5 .09). Forty-three patients (41.7%) had LPS-induced TNF-a responses less than 200 pg/mL, indicating severe suppression of the TLR4 pathway (Fig 1, B) . TNF-a production after LPS stimulation was strongly correlated (Spearman rho) with production of IL-6 and IL-8 (r > _ 0.83; P < .0001), indicating pathway suppression (see Fig E2 in this article's Online Repository at www.jacionline.org). Table E2 in this article's Online Repository at www.jacionline.org presents the median (interquartile range) values for poly(I:C)-and LPS-induced production of IFN-a and TNF-a, respectively. As with suppression of the IFN-a response, subjects with severe suppression of the TNF-a response had greater severity of illness (see Table E3 in this article's Online Repository at www.jacionline.org). They also had fewer ventilator-free days, and longer durations of PICU and hospital stay compared with children with a higher TNF-a response. Nearly a third of all Subjects' IFN-a response was characterized into 3 groups on the basis of ex vivo whole blood IFN-a production after 24 hours of unstimulated control incubation (white boxes) and poly(I:C) stimulation (gray boxes). Suppressed subjects had low production of IFN-a in both unstimulated controls and poly(I:C)-stimulated blood samples, with a low delta (no significance [NS] vs control), n 5 56. Peaked subjects had high production of IFN-a in both unstimulated controls and poly(I:C)-stimulated samples, with a low delta (NS vs control), n 5 11. Those who Responded had variable IFN-a levels in unstimulated controls but were able to produce an increase in their poly(I:C) stimulated blood, with a high delta (P < .0001 vs control), n 5 38 based on the Wilcoxon matched-pairs signed rank test. Data represent samples collected 72 hours or earlier from PICU admission. B, LPS-induced TNF-a production. In the LPS-stimulated samples categorized as TNF-a greater than or equal to or less than 200 pg/mL, unstimulated control samples had similar values (P 5 .09) whereas TNF-a responses were significantly different (P < .0001) based on the Mann-Whitney U test. C, Poly(I:C)-induced IFN-a response groups with LPS-induced TNF-a response data. Gray bars represent subjects whose LPS-induced TNF-a response was less than 200 pg/mL, whereas white bars represent those with a TNF-a response greater than or equal to 200 pg/mL. Subjects with Suppressed IFN-a were more likely to have a low TNF-a response compared with Responders or those with a Peaked IFN-a response (Pearson x 2 P < .0002).
subjects (33 of 103; 32%) had suppression of both the IFN-a response (RIG-I pathway) and the TNF-a response (TLR4 pathway) (Table II) . Children with dual suppression of both pathways had higher maximum organ failure scores based on Pediatric Logistic Organ Dysfunction score (of which 70% occurred on the day of admission), the fewest ventilator-free days, and the longest hospital stays compared with all other subjects, and included all 4 fatalities in the cohort. Fig 1, C, shows that subjects in the IFN-a Suppressed group were more likely to have a TNF-a response less than 200 pg/mL compared with the Peaked or Responded group (P < .0002). Suppression of both pathways within 72 hours of admission was associated with increased incidence of prolonged multiple-organ dysfunction syndrome (Fig 2, A) and AHRF (> _7 days) (Fig 2, B) compared with those without dual pathway suppression (30.3% vs 8.6%, P 5 .003 and 39.4% vs 11.4%, P 5 .001, respectively). For univariate associations between immune function and outomes, see Table E4 in this article's Online Repository at www.jacionline. org. Multivariable logistic regression analysis revealed that among the 92 subjects with WBC data available, the presence of early, dual pathway suppression was independently associated with greater adjusted odds of developing prolonged AHRF, whereas a higher WBC count was protective (Table III) .
A similar analysis of all 103 subjects with dual stimulation data available, excluding WBC as a covariable, demonstrated that the dual suppression was independently associated with prolonged AHRF (adjusted odds ratio, 4.7; 95% CI, 1.4-15.8; P 5
.01). The 10 children who had severe TNF-a suppression but were not IFN-a Suppressed experienced a better overall PICU clinical course compared with the dually suppressed subjects (see Table E5 in this article's Online Repository at www. jacionline.org) and all had influenza A (P 5 .01). Bacterial coinfections on presentation were significantly more common in patients with suppressed pathway responses. Of these identified pathogens, S aureus was detected in 42% of patients (Table II) . Dually suppressed patients had nearly triple the incidence of S aureus coinfections compared with all others in the cohort (42.4% vs 14.3%; P 5 .002).
Serum cytokine levels measured in unstimulated blood samples drawn at the same time as the stimulation studies were compared for each response group (see Fig E3 in this article's Online Repository at www.jacionline.org). Subjects with dual pathway suppression (n 5 33) had significantly higher serum levels of IL-6 and IL-8 compared with other subjects, whereas serum IFN-a and IL-10 levels were similar between groups.
Longitudinal analysis of the IFN-a response
Sixty patients had a second blood collection for poly(I:C) stimulation performed approximately 70 hours (median; interquartile range, 49-72) after their initial test. Patients whose second collection was more than 130 hours from the first were excluded. Twenty-six of 60 patients (43.3%) showed IFN-a suppression after both tests (see Table E6 in this article's Online Repository at www.jacionline.org). Children with this prolonged suppression were significantly more likely to have influenza B infection than influenza A (P 5 .001) or coinfection with S aureus (P 5 .02) compared with children who did not have persistent suppression. All 4 deaths in the cohort were children with prolonged IFN-a suppression. Those who initially Peaked or Responded after the first poly(I:C) test were unlikely to show suppression at the second time point.
DISCUSSION
We assessed ex vivo immune responsiveness of blood samples from critically ill children with influenza to the viral mimic poly(I:C)-LMW/LyoVec and the innate immune stimulant LPS by measuring IFN-a and TNF-a production, representing the 2 different pathogen recognition pathways RIG-I and TLR4, respectively. To our knowledge, this is the first report to show that suppression of the antiviral RIG-I pathway is associated with adverse outcomes from critical influenza infection in children who were thought to have intact immune systems at baseline. Furthermore, children whose leukocytes were unable to respond to ex vivo challenges with both poly(I:C) and LPS had a greater degree and longer duration of organ failure, with associated increases in durations of mechanical ventilation and hospital stay compared with children with more intact immune responses.
Dual pathway suppression within the first 72 hours of admission was independently associated with greater odds of developing prolonged AHRF, even after adjusting for WBC count. The proportion of children whose IFN-a response had peaked in response to active influenza infection (high unstimulated values that failed to increase with poly(I:C) stimulation) showed outcomes similar to those who responded to ex vivo stimulation. Combining the results of RIG-I pathway testing with assessment of TLR4 pathway suppression resulted in a stronger association with prolonged (> _7 days) multiple-organ dysfunction and prolonged severe hypoxic respiratory failure in influenza-infected children.
To initiate the signaling cascade for RIG-I-induced IFN production, viruses with short nucleotides must first be detected intracellularly by cytoplasmic RIG-I, a key host cell pattern recognition receptor. This is vital for host protection especially against influenza by recognizing its 59-triphosphate single-stranded RNA. 12 Truncated poly(I:C)-LMW/LyoVec was formulated to improve cellular uptake and is primarily recognized by RIG-I. 13 Longer segments of the poly(I:C)-LMW/LyoVec have potential to activate the RIG-I-like helicase melanoma differentiation-associated gene-5 receptor, which primarily results in the production of IFN-b, along with a relatively small amount of IFN-a. 13 After RIG-I recognition, the genetically conserved IFN-a2 subtype is among the second round of cytokines to be rapidly produced after IFN-a1 and IFN-b. 25, 26 Measuring an increase in IFN-a2 in stimulated blood samples ensured RIG-I recognition as well as completion of its complex pathway to mount a viral response. We also measured IFN-b in the poly(I:C)-stimulated supernatants and found that IFN-a-Suppressed patients were similarly unable to generate IFN-b but Responded patients did (P 5 .05; data not shown). This supports the hypothesis that signaling across the RIG-I family of receptors was suppressed or inhibited in these patients. IL-6 and TNF-a were also measured after poly(I:C) stimulation, and the IFN-a-Suppressed group consistently showed low cytokine production, suggesting that the immune suppression was not solely limited to IFN-a. It was also true that TNF-a levels after LPS stimulation were strongly correlated with stimulated levels of IL-6 and IL-8 in the same samples. It is therefore plausible that it is not the individual pathways, but rather a downstream point where the RIG-I and TLR4 pathways converge that is being affected.
Our study confirms previous findings that suppression of the TLR4 pathway is associated with worse clinical outcomes in critically ill children with influenza. 14, 22 Our independent cohort of children without underlying immune conditions also highlighted the association between severe suppression of the TLR4 pathway and longer duration of organ failure and increased mortality. 22, 23 The addition of poly(I:C) stimulation allowed us to identify subjects who are at even greater risk for influenza-related adverse outcomes. A quarter of subjects with severe suppression of the TLR4 pathway had intact RIG-I pathway responses and better outcomes than dually suppressed subjects. Similarly, use of LPS stimulation alone would have resulted in failure to identify 22 of 103 subjects (21%) who showed suppressed IFN-a responses despite a more robust TNF-a response. Given the more pathogen-specific nature of the RIG-I pathway in the setting of influenza infection, it is likely that evaluation of both pathways will be important in future immunomodulatory trials and in identifying children at greatest risk of adverse outcomes.
Within our suppressed patient population, there was an increased incidence of bacterial coinfections. It is not known whether these patients mounted an endogenous IFN response upon their initial exposure to influenza. However, during primary exposure to the virus, the host can become vulnerable to secondary bacterial infections due to a polarizing immune reaction to the virus followed by a period of IFN exhaustion. [27] [28] [29] Commensal bacteria such as S aureus and Streptococcus pneumoniae are the most common cause of secondary infections, and are known to be associated with increased morbidity and mortality in children with influenza, 30 which is in agreement with our results. S aureus has also been shown to inhibit influenza (and its isolated RNA) from inducing downstream IFN-stimulating genes in vitro. 31 It has been shown that specific S aureus peptides can disrupt proinflammatory signaling via TLR4 as well, 32 potentially explaining the suppression of the TNF-a response we saw in our S aureus-infected subjects.
Multicenter translational studies of immune function in pediatric critical illness are challenging. Such studies are limited by the small blood volumes available for study, a relatively small patient population necessitating a large number of study sites, and technical challenges associated with sample processing. Ex vivo stimulation studies have proven to be an effective approach to overcoming some of these challenges. Through the central production and quality control of stimulation kits, simple protocols, the use of low-blood-volume assays, and central cytokine determination, we were able to demonstrate the feasibility of functional immunophenotyping across 24 pediatric centers. Most children in this cohort were previously healthy and all had no prior documented immune compromise. Children with risk factors for developing life-threatening influenza infection were excluded. Because this is the first study of its kind using ex vivo poly(I:C)-LMW/LyoVec to stimulate a small volume of blood from a specific pediatric population, the IFN-a thresholds we chose on the basis of our optimization assays warrant confirmatory studies.
This study has several important limitations. First, despite having 24 sites, our sample size is relatively small, with only 4 deaths in the cohort. Ours is, however, among the largest cohorts of children with critical influenza to be reported, and the high degree of observed morbidity (multiple-organ dysfunction syndrome, respiratory failure) suggests that we captured children with highly clinically relevant disease who merit further study. Our evaluation of immune function was also relatively narrow in scope. We cannot comment, for example, on antigen presentation, T-cell responses, antibody responses, or mucosal antiviral immunity; nor can we comment on the degree to which poly(I:C) was internalized by target cells. We chose instead to focus on ex vivo stimulation testing as a window into the responsiveness of 2 pathophysiologically relevant signaling pathways. The strong relationships between reduced RIG-I/TLR4 pathway function and clinical outcomes suggests that this approach may be useful for subject stratification in future clinical trials. Although the supernatants from these stimulation experiments were batched for later analysis in the current study, we are using a similar technique to drive real-time treatment decision making in 2 ongoing clinical trials focused on immune stimulation in pediatric critical illness (NCT01495637, NCT03769844). In these studies, the stimulation supernatants are analyzed less than 24 hours from the time of collection, permitting next-day treatment allocation based on patient-specific immunophenotyping. This highlights the utility of this approach to immune testing and is deserving of future study in children with critical influenza. The performance of complete blood cell counts was not protocolized in the current study; rather, we used clinically ordered complete blood cell count data. It is therefore difficult to comment definitively on the role of leukopenia versus reduced leukocyte function as an explanation for reduced IFN-a and TNF-a responses in our subjects. Finally, it is possible that impairment of the RIG-I and TLR4 pathways may simply represent a marker of severity of illness rather than a pathophysiological contributor to adverse outcomes. Although this study was not designed to explore this issue, it does provide strong biologic plausibility in support of the design and execution of immunomodulatory studies to test the hypothesis that restoration of RIG-I and TLR4 pathway function may improve outcomes in critically ill children with influenza.
Our current study provides additional insight into the pathophysiology of influenza-associated respiratory failure in children. Influenza-infected, critically ill children who show severe impairment of their ability to produce IFN-a and TNF-a in response to ex vivo whole blood stimulation with poly(I:C) and LPS had worse clinical outcomes compared with children with intact immune responses or impairment of the RIG-I or TLR4 pathway alone. Future studies of immune suppression in critically ill children with influenza should continue to evaluate these relationships. Clinical trials aimed at restoring immune responsiveness in this population should incorporate testing of both pathways to effectively stratify subjects into treatment arms and to enrich the studies with subjects who have the potential to benefit from improving immune function across multiple important immunologic pathways.
Key messages
d In a multicenter cohort of previously immunocompetent influenza-infected critically ill children, suppression of both the RIG-I and TLR4 signaling pathways in leukocytes is associated with adverse outcomes.
METHODS
Clinical outcome definitions
Acute respiratory distress syndrome (ARDS) was defined as acute onset of hypoxemia (PaO2/FiO2 ratio of either < _300 for mild or < _200 for moderate to severe ARDS) with bilateral infiltrates on chest radiograph and no evidence of left heart failure. E1 Vasopressor-dependent septic shock was defined as receiving dopamine more than 5 mg/kg/min and/or any epinephrine, norepinephrine, or phenylephrine infusion to maintain normal hemodynamics. Ventilator-free days was defined as days alive and free of invasive or noninvasive mechanical ventilation up to 28 days. E2 Bacterial coinfections were defined as the growth of an organism from endotracheal, blood, and/or pleural fluid cultures within 72 hours of PICU admission, as previously described. E3 Organ dysfunction was measured daily (days 1, 2, 3, 4, 7, 14, and 28 ), using the Pediatric Logistic Organ Dysfunction-1 score E4 values closest to 08:00 am. Each patient's highest Pediatric Logistic Organ Dysfunction score over these days was used as an outcome. Prolonged organ dysfunction outcome included children with multiple-organ dysfunction syndrome on/after day 7 or extracorporeal membrane oxygenation on/after day 7, and in this cohort, incorporated nonsurvivors. Patients with prolonged AHRF had a PaO2/FiO2 ratio of less than 200 (consistent with moderate to severe acute respiratory distress syndrome) and were also on mechanical ventilator support on/after day 7 of PICU admission.
Statistical analyses
Pearson x 2 test was used for categorical variables, with likelihood ratios as appropriate. Kruskall-Wallis test, Wilcoxon matched-pairs signed rank test, or Mann-Whitney U test was used for continuous variables where appropriate. A 2-tailed P value of less than .05 was considered significant. Multivariable logistic regression was used to evaluate relationships between immune suppression and the development of prolonged (> _7 days) AHRF. Variables with P value of less than .20 were included in the final models.
General methods
Stimulations were conducted using study-provided kits and protocols, following study-specific training. Poly(I:C) reagents were provided to study sites by A.G.R. The LPS stimulation solution was manufactured at the Immune Surveillance Laboratory at the Research Institute at Nationwide Children's Hospital (provided by M.H.) and shipped to Pediatric Intensive Care Influenza sites on a monthly basis. Each shipment was quality controlled such that the intrabatch coefficients of variation for LPS-stimulated TNF-a production (when tested using healthy donor blood) was less than 10%.
To measure serum IFN-a2, TNF-a, IL-8, IL-6, and IL-10, the Luminex Millipore magnetic bead multiplex array, Luminex 200 platform, Bioplex Analysis 5.1 software (EMD Millipore, Billerica, Mass) was used. The lower limit of detection was determined to be 0.9, 0.2, 0.05, 0.09, and 0.5 pg/mL, respectively. Serum IFN-b was assessed using the single target Verikine ELISA from PBL Assay Science (Piscataway, NJ), with 5.9 pg/mL as the lower limit of detection.
Poly(I:C) assay development
To optimize the amount of poly(I:C)-LMW/LyoVec to use, whole blood from 4 healthy volunteers was stimulated as shown in Table E1 . Just before use, 500 mL of endotoxin-free water was added to the poly(I:C) supplied as a 25-mg vial of lyophilized powder to obtain a stock solution of 50 mg/mL and allowed to solubilize for 15 minutes at room temperature. This was stored at 48C while blood was being obtained. For the incubation media, 100 mL of FBS (Gemini Bio-Products, West Sacramento, Calif) was added to 900 mL of Corning cellgro RPMI 1640 with L-Glutamine (Fisher Scientific, Waltham, Mass) and 150 mL aliquoted into four 1.5-mL sterile, Seal-Rite microcentrifuge tubes (USA Scientific, Ocala, Fla) per patient: 2 for the stimulation and 2 for the control. Then, 50 mL of heparinized whole blood was added to each tube. From the 50 mg/mL poly(I:C) stock solution, 0.4, 2, and 4 mL was added to each stimulation tube to achieve 0.1, 0.5, and 1 mg/ mL, respectively, as final concentrations. All tightly sealed tubes were placed into a 378C waterbath for 24 hours. After the incubation, the tubes were centrifuged at 1000g (RCF) for 5 minutes. The supernatant from each tube was pipetted into new, appropriately labeled microcentrifuge tubes and stored at 2808C.
Based on these initial results, a final concentration of 0.5 mg/mL poly(I:C) was chosen for a preliminary study during the 2010 to 2011 influenza season and performed with blood from 34 children. Many of those infected with influenza had low WBC counts, leading to more than half the children having nondetectable IFN-a2 levels in their stimulated samples. Therefore, we modified the protocol to increase the blood volume in each stimulation from 50 mL to 150 mL, keeping the media volume at 150 mL. Poly(I:C) was also increased so that 0.74 mg/mL was the final, optimized concentration used for blood stimulation tests from 2012 to 2015, which represents the data presented here. .01 Bacterial coinfection .01 WBC count (n 5 92)
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PrAHRF, Prolonged acute hypoxemic respiratory failure. Only includes patients with dual suppression data available (n 5 103 unless otherwise noted). Boldface indicates P < .05. 
